|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/28 | |||
| G01N 33/569 |
| (11) | Patento numeris | 2782599 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12795715.7 |
| Europos patento paraiškos padavimo data | 2012-11-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-10-01 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-10-16 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2012/066345 |
| Data | 2012-11-21 |
| (87) | Numeris | WO 2013/078375 |
| Data | 2013-05-30 |
| (30) | Numeris | Data | Šalis |
| 201161563430 P | 2011-11-23 | US | |
| 201261599221 P | 2012-02-15 | US |
| (72) |
BORIE, Dominique, US
HSU, Hailing, US
PAN, Wei-jian, US
REES, William, US
SULLIVAN, Barbara, US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive Dept. 4300 M/S 27-4-A, Thousand Oaks, CA 91320-1799,
US
|
| (54) | ADMINISTRATION OF ALPHA4BETA7 HETERO-DIMER-SPECIFIC ANTIBODY |
| ADMINISTRATION OF ALPHA4BETA7 HETERO-DIMER-SPECIFIC ANTIBODY |